Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

abbvie ag - leuprorelinum - pulver und lösungsmittel zur herstellung einer depot-injektionssuspension in einer fertigspritze - praeparatio sicca: leuprorelini acetas 3.75 mg corresp. leuprorelinum 3.57 mg, gelatina, poly(lactidum-co-glycolidum), mannitolum, pro vitro. solvens: carmellosum natricum corresp. natrium 0.54 mg, mannitolum, polysorbatum 80, acidum aceticum glaciale, aqua ad iniectabile q.s. ad solutionem pro 1 ml. - prostatico, endometriosi, tumori della mammella, centrale pubertà anticipata - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

debiopharm research & manufacturing sa - triptorelinum - poudre et solvant pour suspension injectable à libération prolongée - praeparatio cryodesiccata: triptorelinum 3.75 mg ut triptorelini embonas, poly(lactidum-co-glycolidum), mannitolum, carmellosum natricum corresp. natrium 2.2 mg, polysorbatum 80, pro vitro. solvens: aqua ad iniectabile 2 ml. - analogo sintetico del gnrh / lhrh - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

ferring ag - triptorelinum - polvere e solvente per sospensione iniettabile - pulver: triptorelinum 3.75 mg ut triptorelini acetas hydricus, poly(lactidum-co-glycolidum), propylenglycoli dicaprylocapras pro praeparatione. solvens: polysorbatum 80, dextranum 70, natrii chloridum, natrii dihydrogenophosphas dihydricus, natrii hydroxidum, aqua ad iniectabile q.s. ad solutionem pro 1 ml corresp. natrium 3.43 mg. - hormonabhängiges prostatico,endometriosi,downregulation in reproduktionsmed.,centrale pubertà anticipata - biotechnologika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

abbvie ag - leuprorelinum - pulver und lösungsmittel zur herstellung einer depot-injektionssuspension in einer fertigspritze - praeparatio sicca: leuprorelini acetas 11.25 mg corresp. leuprorelinum 10.72 mg, acidum poly-(s)-lacticum, mannitolum, pro vitro. solvens: carmellosum natricum corresp. natrium 0.54 mg, mannitolum, polysorbatum 80, acidum aceticum glaciale q.s. ad ph, aqua ad iniectabile q.s. ad solutionem pro 1 ml. - prostatico, endometriosi, tumori della mammella - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

labatec pharma sa - leuprorelinum - poudre et solvant pour suspension injectable à libération prolongée en seringue préremplie - poudre: leuprorelini acetas 3.75 mg corresp. leuprorelinum 3.57 mg, poly(lactidum-co-glycolidum), triethylis citras, mannitolum, carmellosum natricum corresp. natrium 1.3 mg, polysorbatum 80, pro vitro. solvens: mannitolum, acidum hydrochloridum ad ph, natrii hydroxidum ad ph, aqua q.s. ad solutionem pro 2 ml. - il carcinoma della prostata - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

labatec pharma sa - leuprorelinum - poudre et solvant pour suspension injectable à libération prolongée en seringue préremplie - poudre: leuprorelini acetas 22.5 mg corresp. leuprorelinum 21.42 mg, acidum polylacticum, triethylis citras, mannitolum, carmellosum natricum corresp. natrium 2.2 mg, polysorbatum 80, pro vitro. solvens: mannitolum, acidum hydrochloridum ad ph, natrii hydroxidum ad ph, aqua ad iniectabile q.s. ad solutionem pro 2 ml. - il carcinoma della prostata - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

debiopharm research & manufacturing sa - triptorelinum - poudre et solvant pour suspension injectable à libération prolongée - praeparatio cryodesiccata: triptorelinum 3.75 mg ut triptorelini embonas, poly(lactidum-co-glycolidum), mannitolum, carmellosum natricum corresp. natrium 2.2 mg, polysorbatum 80, pro vitro. solvens: aqua ad iniectabile 2 ml. - analogo sintetico del gnrh / lhrh - synthetika

Unione Europea - italiano - EMA (European Medicines Agency)

accord healthcare s.l.u. - leuprorelin mesilate - neoplasie prostatiche - terapia endocrina - camcevi is indicated for the treatment of hormone dependent advanced prostate cancer and for the treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy.